Soru

Zorluk: ZorDepressive Disorders

A 61-year-old retired engineer is brought to the physician by his daughter for a psychiatric evaluation. Over the past five weeks, he has become increasingly withdrawn, spending most of the day in bed. He reports waking up at 3:00 AM daily and being unable to return to sleep. His daughter notes he has lost approximately 5.5 kg (12 lb) during this period and no longer shows interest in his usual hobbies, such as gardening. Two weeks ago, the patient's primary care provider diagnosed him with a major depressive episode and prescribed fluoxetine. The patient states he feels no better and wants to discontinue the medication. Upon further questioning, the daughter recalls that when her father was in his late thirties, he was briefly given a different antidepressant for sadness. Within days of starting that medication, he became excessively talkative, slept only two hours a night for a week, and impulsively bought three luxury vehicles, leading to a brief psychiatric hospitalization. Medical history is otherwise unremarkable, and he takes no other medications. Vital signs are within normal limits. Which of the following is the most appropriate next step in management?

  1. Discontinue fluoxetine and initiate quetiapineCevap
  2. B
    Maintain the current fluoxetine dose and schedule a follow-up in 4 weeks
  3. C
    Discontinue fluoxetine and immediately initiate tranylcypromine
  4. D
    Increase the dosage of fluoxetine to target the severe melancholic symptoms
  5. E
    Continue fluoxetine and add bupropion to target the profound anhedonia

Cevap

Discontinue fluoxetine and initiate quetiapine
This patient is currently experiencing a severe depressive episode, characterized by melancholic features such as terminal insomnia (waking at 3:00 AM), anhedonia, and weight loss. Crucially, his history reveals an episode of severely elevated mood, decreased need for sleep, impulsivity, and hospitalization that occurred after antidepressant exposure. This presentation meets the criteria for a manic episode (antidepressant-induced mania is considered indicative of underlying Bipolar I disorder if the manic symptoms persist beyond the physiological effect of the drug, or in classical definitions, dictates a bipolar spectrum approach). For patients with bipolar depression, standard antidepressant monotherapy (like fluoxetine) is contraindicated as it carries a high risk of inducing a manic switch or rapid cycling. The appropriate next step is to immediately discontinue the fluoxetine and initiate a medication approved for bipolar depression, such as quetiapine, lurasidone, or lithium.

Adım Adım Çözüm

1
Analyze the current clinical presentation.
The patient exhibits a major depressive episode with melancholic features (terminal insomnia, significant weight loss, profound anhedonia).
Establishing the current affective state is required for guiding immediate pharmacotherapy.
2
Evaluate the patient's psychiatric history.
The patient had a previous episode of decreased need for sleep, hyper-verbal speech, and impulsivity requiring hospitalization shortly after starting an antidepressant.
A history of mania or hypomania fundamentally changes the diagnosis from Major Depressive Disorder (unipolar) to Bipolar Disorder.
3
Determine the appropriate pharmacologic management based on the revised diagnosis.
The diagnosis is Bipolar I disorder, currently in a depressive episode. The current treatment (fluoxetine monotherapy) is contraindicated.
Antidepressant monotherapy can trigger manic episodes in bipolar patients. The SSRI must be stopped, and a medication efficacious for bipolar depression (e.g., quetiapine, lurasidone, or lithium) should be initiated.

Anahtar Kavram

Patients presenting with a depressive episode must be rigorously screened for a history of mania or hypomania prior to initiating, or continuing, antidepressant therapy. Antidepressant monotherapy is contraindicated in Bipolar Disorder due to the risk of inducing mania.
Tahmini Süre:1m 30s
Bu soruyu puanla